United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 4,000 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 4,000 shares of the stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $483.28, for a total transaction of $1,933,120.00. Following the sale, the chief executive officer directly owned 130 shares of the company’s stock, valued at $62,826.40. The trade was a 96.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

United Therapeutics Price Performance

NASDAQ UTHR traded down $9.80 on Monday, hitting $479.51. The stock had a trading volume of 468,634 shares, compared to its average volume of 581,703. The business’s fifty day moving average price is $452.91 and its 200 day moving average price is $368.72. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $492.62. The stock has a market cap of $20.65 billion, a price-to-earnings ratio of 18.17, a price-to-earnings-growth ratio of 4.86 and a beta of 0.86.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, beating the consensus estimate of $6.89 by $0.27. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The firm had revenue of $799.50 million during the quarter, compared to analyst estimates of $812.87 million. During the same quarter in the prior year, the business posted $6.39 EPS. The business’s revenue for the quarter was up 6.8% compared to the same quarter last year. As a group, sell-side analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current year.

Analyst Ratings Changes

Several brokerages have weighed in on UTHR. Oppenheimer raised their price target on United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a report on Friday, September 5th. HC Wainwright increased their price objective on shares of United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. UBS Group lifted their target price on shares of United Therapeutics from $580.00 to $600.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Cantor Fitzgerald upped their price target on shares of United Therapeutics from $405.00 to $525.00 and gave the company an “overweight” rating in a research note on Wednesday, September 10th. Finally, Bank of America lifted their price objective on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 2nd. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $505.00.

Institutional Trading of United Therapeutics

Several large investors have recently made changes to their positions in UTHR. Vanguard Group Inc. raised its holdings in shares of United Therapeutics by 0.3% during the first quarter. Vanguard Group Inc. now owns 4,457,135 shares of the biotechnology company’s stock worth $1,374,001,000 after purchasing an additional 15,312 shares during the last quarter. AQR Capital Management LLC boosted its holdings in United Therapeutics by 40.1% in the second quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock valued at $362,876,000 after purchasing an additional 364,713 shares during the last quarter. Invesco Ltd. grew its position in United Therapeutics by 90.2% during the 2nd quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock worth $254,219,000 after purchasing an additional 419,588 shares during the period. Darwin Global Management Ltd. purchased a new position in shares of United Therapeutics during the 3rd quarter valued at about $317,617,000. Finally, Assetmark Inc. raised its stake in shares of United Therapeutics by 38.1% during the 2nd quarter. Assetmark Inc. now owns 715,834 shares of the biotechnology company’s stock valued at $205,695,000 after buying an additional 197,384 shares during the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.